Xeris Biopharma Holdings, Inc. Quarterly Deferred Income Tax Expense (Benefit) in USD from Q1 2023 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
Xeris Biopharma Holdings, Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from Q1 2023 to Q1 2024.
  • Xeris Biopharma Holdings, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was $307K.
  • Xeris Biopharma Holdings, Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was -$1.25M, a 12.3% increase from 2022.
  • Xeris Biopharma Holdings, Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was -$1.42M.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $307K +$307K Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q1 2023 $0 Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.